PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Non-surgical treatment - Market size and forecast 2018-2023 • Surgical treatment - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bayer AG • Johnson & Johnson Services, Inc. • Novartis AG • Pfizer Inc. • Teva Pharmaceutical Industries Ltd. PART 15: APPENDIX • Research methodology • List of abbreviations PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Phase III pipeline molecules: Overview Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Non-surgical treatment - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Non-surgical treatment - Year-over-year growth 2019-2023 (%) Exhibit 22: Surgical treatment - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Surgical treatment - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Bayer AG - Vendor overview Exhibit 49: Bayer AG - Business segments Exhibit 50: Bayer AG - Organizational developments Exhibit 51: Bayer AG - Geographic focus Exhibit 52: Bayer AG - Segment focus Exhibit 53: Bayer AG - Key offerings Exhibit 54: Bayer AG - Key customers Exhibit 55: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 56: Johnson & Johnson Services, Inc. - Business segments Exhibit 57: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 58: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 59: Johnson & Johnson Services, Inc. - Segment focus Exhibit 60: Johnson & Johnson Services, Inc. - Key offerings Exhibit 61: Johnson & Johnson Services, Inc. - Key customers Exhibit 62: Novartis AG - Vendor overview Exhibit 63: Novartis AG - Business segments Exhibit 64: Novartis AG - Organizational developments Exhibit 65: Novartis AG - Geographic focus Exhibit 66: Novartis AG - Segment focus Exhibit 67: Novartis AG - Key offerings Exhibit 68: Novartis AG - Key customers Exhibit 69: Pfizer Inc. - Vendor overview Exhibit 70: Pfizer Inc. - Business segments Exhibit 71: Pfizer Inc. - Organizational developments Exhibit 72: Pfizer Inc. - Geographic focus Exhibit 73: Pfizer Inc. - Segment focus Exhibit 74: Pfizer Inc. - Key offerings Exhibit 75: Pfizer Inc. - Key customers Exhibit 76: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 77: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 78: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 79: Teva Pharmaceutical Industries Ltd. - Geographic focus Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 81: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 82: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 83: Validation techniques employed for market sizing

Bayer AG Johnson & Johnson Services, Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd.